- Results from a randomized controlled trial (RCT) suggest that the histamine H4 receptor antagonist ZPL-3893787 is associated with clinical improvement in patients with atopic dermatitis (AD).
Why this matters
- ZPL-3893787 may represent a promising new treatment option for AD, which is needed for patients with moderate to severe disease not adequately controlled with topical agents.
- At 8 weeks, ZPL-3893787 was associated with a greater reduction in the Eczema Area and Severity Index (50% vs 27%, P=.010) and in Scoring Atopic Dermatitis (41% vs 26%, P=.004).
- ZPL-3893787 and placebo were associated with 18.5% and 9.1% of patients, respectively, considered to be clear or almost clear by Investigator’s Global Assessment (P=.088).
- ZPL-3893787 and placebo were associated with similar reductions in pruritus (P=.249).
- ZPL-3893787 and placebo were associated with similar incidence of treatment-emergent adverse events (66% vs 64%).
- 98 patients with moderate to severe AD from 17 centers in 4 countries were randomly assigned 2:1 to receive ZPL-3893787 (N=65) or placebo (N=33) for 8 weeks, and analyzed for efficacy and safety.
- Funding: Ziarco Pharma Ltd.
- Small patient sample size.
- Short study time.